CBD and Avidekel hold their own against popular Copaxone®
ENFLEUR is happy to share a new study published by Inflammopharmocology, a journal publishing in the field of inflammation and its pharmacological control emphasizing pain therapy, compared the therapeutic efficacy of a popular MS drug, Copaxone® (glatiramer acetate) with CBD as well as Avidikel, a high-CBD, low-THC strain of cannabis. The results found that in mice models CBD and purified Avidikel extracts are as efficient as Copaxone® in relieving the symptoms of experimental autoimmune encephalomyelitis, which is the most commonly used experimental model for multiple sclerosis. The results of this study are hopeful in terms of possible future alternatives to Copaxone® with a fair amount of common, yet undesirable side-effects.
In light of these findings, integrating a quality, high potency broad or full-spectrum CBD product into a daily wellness routine is a worthwhile consideration for those living with MS.
Why does this matter? Study shows that both CBD and Avidikel, a high-CBD, low-THC strain of cannabis, are equally as effective as common MS drug, Copaxone®.